These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 32941929)

  • 61. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease.
    Kumar K; Kumar A; Keegan RM; Deshmukh R
    Biomed Pharmacother; 2018 Feb; 98():297-307. PubMed ID: 29274586
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Diverse molecular targets for therapeutic strategies in Alzheimer's disease.
    Han SH; Mook-Jung I
    J Korean Med Sci; 2014 Jul; 29(7):893-902. PubMed ID: 25045220
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
    Long JM; Holtzman DM
    Cell; 2019 Oct; 179(2):312-339. PubMed ID: 31564456
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.
    Novakovic D; Feligioni M; Scaccianoce S; Caruso A; Piccinin S; Schepisi C; Errico F; Mercuri NB; Nicoletti F; Nisticò R
    Drug Des Devel Ther; 2013; 7():1359-64. PubMed ID: 24255592
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders.
    Lasheen NN; Allam S; Elgarawany A; Aswa DW; Mansour R; Farouk Z
    J Physiol Sci; 2024 Sep; 74(1):46. PubMed ID: 39313800
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.
    Vander Zanden CM; Chi EY
    J Pharm Sci; 2020 Jan; 109(1):68-73. PubMed ID: 31647950
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tau-targeted treatment strategies in Alzheimer's disease.
    Götz J; Ittner A; Ittner LM
    Br J Pharmacol; 2012 Mar; 165(5):1246-59. PubMed ID: 22044248
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer's Disease?
    Doig AJ; Del Castillo-Frias MP; Berthoumieu O; Tarus B; Nasica-Labouze J; Sterpone F; Nguyen PH; Hooper NM; Faller P; Derreumaux P
    ACS Chem Neurosci; 2017 Jul; 8(7):1435-1437. PubMed ID: 28586203
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
    Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
    J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-beta Complexities and Pioneering Precision Medicine Approaches.
    Patwekar M; Patwekar F; Khan S; Sharma R; Kumar D
    Curr Top Med Chem; 2024; 24(19):1665-1682. PubMed ID: 38644708
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.
    Buccellato FR; D'Anca M; Tartaglia GM; Del Fabbro M; Scarpini E; Galimberti D
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762203
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Development of Disease-modifying Therapy for Alzheimer's Disease].
    Akiyama H
    Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?
    Villain N
    Rev Neurol (Paris); 2022 May; 178(5):437-440. PubMed ID: 35489824
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Alzheimer's disease: from pathogenesis to disease-modifying approaches.
    Galimberti D; Scarpini E
    CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):163-74. PubMed ID: 21222635
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Therapeutic news in Alzheimer’s disease: soon a disease-modifying therapy?].
    Villain N
    Geriatr Psychol Neuropsychiatr Vieil; 2022 Jun; 20(2):256-260. PubMed ID: 35929392
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mathematical model on Alzheimer's disease.
    Hao W; Friedman A
    BMC Syst Biol; 2016 Nov; 10(1):108. PubMed ID: 27863488
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tau Protein Aggregation in Alzheimer's Disease: Recent Advances in the Development of Novel Therapeutic Agents.
    Monteiro KLC; Alcântara MGDS; de Aquino TM; da Silva-Júnior EF
    Curr Pharm Des; 2020; 26(15):1682-1692. PubMed ID: 32286939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.